Oncostatin M inhibits TGF-β1-induced CTGF expression via STAT3 in human proximal tubular cells

Biochemical and Biophysical Research Communications

Volumn 424, Issue 4, 2012, Pages 801-806

  Sarközi, Rita ^a   Flucher, Kathrin ^a   Haller, Viktoria Maria ^a   Pirklbauer, Markus ^a   Mayer, Gert ^a   Schramek, Herbert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

CTGF; Oncostatin M; Proximal tubular epithelial cells; SMAD3; STAT3; TGF 1

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; ONCOSTATIN M; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL STIMULATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TIME; UPREGULATION;

CELL LINE; CONNECTIVE TISSUE GROWTH FACTOR; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; KIDNEY TUBULES, PROXIMAL; ONCOSTATIN M; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 84864810816     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.07.042     Document Type: Article

References (28)

1. Bornstein P., Sage E.H. Matricellular proteins: extracellular modulators of cell function. Curr. Opin. Cell Biol. 2002, 14:608-616.
2. Jun J.I., Lau L.F. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat. Rev. Drug Discovery 2011, 10:945-963.
3. Rachfal A.W., Brigstock D.R. Structural and functional properties of CCN proteins. Vitam. Horm. 2005, 70:69-103.
4. Phanish M.K., Winn S.K., Dockrell M.E.C. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 2010, 114:e83-e92.
5. van Nieuwenhoven F.A., Jensen L.J.N., Flyvbjerg A., Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point?. Nephrol. Dial. Transplant. 2005, 20:6-10.
6. Roestenberg P., van Nieuwenhoven F.A., Joles J.A., Trischberger C., Martens P.P., Oliver N., Aten J., Höppener J.W., Goldschmeding R. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am. J. Physiol. Renal Physiol. 2006, 290:F1344-F1354.
7. Wahab N.A., Schaefer L., Weston B.S., Yiannikouris O., Wright A., Babelova A., Schaefer R., Mason R.M. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005, 48:2650-2660.
8. Riser B.L., Denichilo M., Cortes P., Baker C., Grondin J.M., Yee J., Narins R.G. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J. Am. Soc. Nephrol. 2000, 11:25-38.
9. Adler S.G., Kang S.W., Feld S., Cha D.R., Barba L., Striker L., Striker G., Riser B.L., LaPage J., Nast C.C. Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int. 2001, 60:2330-2336.
10. Wang S., Denichilo M., Brubaker C., Hirschberg R. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int. 2001, 60:96-105.
11. Guha M., Xu Z.G., Tung D., Lanting L., Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007, 21:3355-3368.
12. Yokoi H., Mukoyama M., Mori K., Kasahara M., Suganami T., Sawai K., Yoshioka T., Saito Y., Ogawa Y., Kuwabara T., Sugawara A., Nakao K. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int. 2008, 73:446-455.
13. Riser B.L., Cortes P., DeNichilo M., Deshmukh P.V., Chahal P.S., Mohammed A.K., Yee J., Kahkonen D. Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int. 2003, 64:451-458.
14. Gilbert R.E., Akdeniz A., Weitz S., Usinge W.R., Molineaux C., Jones S.E., Langham R.G., Jerums G. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 2003, 26:2632-2636.
15. Jaffa A.A., Usinger W.R., McHenry M.B., Jaffa M.A., Lipstiz S.R., Lackland D., Lopes-Virella M., Luttrell L.M., Wilson P.W. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1893-1900.
16. Nguyen T.Q., Tarnow L., Andersen S., Hovind P., Parving H.H., Goldschmeding R., van Nieuwenhoven F.A. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2006, 29:83-88.
17. Nguyen T.Q., Tarnow L., Jorsal A., Oliver N., Roestenberg P., Ito Y., Parving H.H., Rossing P., van Nieuwenhoven F.A., Goldschmeding R. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008, 31:1177-1182.
18. Mason R.M. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?. J. Cell. Commun. Signal 2009, 3:95-104.
19. Igarashi A., Okochi H., Bradham D.M., Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol. Biol. Cell 1993, 4:637-645.
20. Gupta S., Clarkson M.R., Duggan J., Brady H.R. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 2000, 58:1389-1399.
21. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 1997, 8:171-179.
22. Okada H., Kikuta T., Kobayashi T., Inoue T., Kanno Y., Takigawa M., Sugaya T., Kopp J.B., Suzuki H.J. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. Am. Soc. Nephrol. 2005, 16:133-143.
23. Sarközi R., Hauser C., Noppert S.J., Kronbichler A., Pirklbauer M., Haller V.M., Grillari J., Grillari-Voglauer R., Mayer G., Schramek H. Oncostatin M is a novel inhibitor of TGF-β1-induced matricellular protein expression. Am. J. Physiol. Renal Physiol. 2011, 301:F1014-F1025.
24. Lan H.Y. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int. J. Biol. Sci. 2011, 7:1056-1067.
25. López-Hernández F.J., López-Novoa J.M. Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012, 347:141-154.
26. Flanders K.C. Smad3 as a mediator of the fibrotic response. Int. J. Exp. Pathol. 2004, 85:47-64.
27. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 2003, 112:1486-1494.
28. Lan H.Y. TGF-β/Smad signaling in diabetic nephropathy. Clin. Exp. Pharmacol. Physiol. 2011 Dec 28, 10.1111/j.1440-1681.2011.05663.x.